EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

Danish Memon, Adam J Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu, Jayon Lihm, Jayalaksmi Miriyala und 21 weitere

Cancer Cell · 2024-02 · 42 (2) · 209-224.e9

DOI: 10.1016/j.ccell.2023.12.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-02. Verfasst von Danish Memon und 32 weiteren Autor:innen. Beteiligte Einrichtung: European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK; Cancer Research UK C…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 234-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Research UK, NCI NIH HHS, Damon Runyon Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFNγ response genes. Upregulation of IFNγ response genes is associated with putative routes of resistance characterized by signatures of persistent IFN signaling, immune dysfunction, and mutations in antigen presentation genes which can be recapitulated in multiple murine models of acquired resistance to PD-(L)1 blockade after in vitro IFNγ treatment. Acquired resistance to PD-(L)1 blockade in NSCLC is associated with an ongoing, but altered IFN response. The persistently inflamed, rather than excluded or deserted, tumor microenvironment of acquired resistance may inform therapeutic strategies to effectively reprogram and reverse acquired resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansAnimalsMiceSignal TransductionImmunotherapyAntigen PresentationB7-H1 AntigenTumor Microenvironment

Stichwörter der Autor:innen

Clonal selectionGenomics and TranscriptomicsImmune escapeImmune-checkpoint blockadeInterferon alpha/gamma responseNeoantigensT cell exhaustionTumor heterogeneityType I and Type II Interferonsanti-PD-1 therapy

Substanzen

B7-H1 Antigen

Autor:innen und Institutionen

  • European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robin…
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Phila…
  • Shattuck Labs, Durham, NC, USA.
  • Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Early Clinical Development, Oncology R&D, AstraZeneca, New York, NY, USA.
  • Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Förderung

  • Cancer Research UK
  • NCI NIH HHS
  • Damon Runyon Cancer Research Foundation
  • Memorial Sloan-Kettering Cancer Center
  • Stand Up To Cancer
  • National Institutes of Health
  • Parker Institute for Cancer Immunotherapy
  • Mark Foundation For Cancer Research

Zitieren

APA

Memon, D., Schoenfeld, A. J., Ye, D., Fromm, G., Rizvi, H., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., Lihm, J., Miriyala, J., Sauter, J. L., Luo, J., Chow, A., Bhanot, U. K., McCarthy, C., Vanderbilt, C. M., Liu, C., …, & Hellmann, M. D. (2024). Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell, 42(2), 209-224.e9. https://doi.org/10.1016/j.ccell.2023.12.013

Vancouver

Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42(2):209-224.e9. doi:10.1016/j.ccell.2023.12.013

BibTeX
@article{Memon2024,
  author = {Memon, Danish and Schoenfeld, Adam J and Ye, Darwin and Fromm, George and Rizvi, Hira and Zhang, Xiang and Keddar, Mohamed Reda and Mathew, Divij and Yoo, Kyung Jin and Qiu, Jingya and Lihm, Jayon and Miriyala, Jayalaksmi and Sauter, Jennifer L and Luo, Jia and Chow, Andrew and Bhanot, Umesh K and McCarthy, Caroline and Vanderbilt, Chad M and Liu, Cailian and Abu-Akeel, Mohsen and Plodkowski, Andrew J and McGranahan, Nicholas and Łuksza, Marta and Greenbaum, Benjamin D and Merghoub, Taha and Achour, Ikbel and Barrett, J Carl and Stewart, Ross and Beltrao, Pedro and Schreiber, Taylor H and Minn, Andy J and Miller, Martin L and Hellmann, Matthew D},
  title = {Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {2},
  pages = {209--224.e9},
  doi = {10.1016/j.ccell.2023.12.013}
}
Kostenlos starten →